Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026

Altimmune advances pemvidutide after positive Phase 2 AUD results, with FDA meeting imminent.

What the company is saying

Altimmune is announcing that results from its RECLAIM Phase 2 trial of pemvidutide in moderate-to-severe alcohol use disorder (AUD) will be presented as a late-breaking oral abstract at The Liver Meeting 2026, highlighting the scientific importance of the findings. The company emphasizes that pemvidutide achieved the primary endpoint—a statistically significant reduction in heavy drinking days versus placebo—and met key FDA-validated secondary endpoints, including reductions in WHO Risk Drinking Levels and achieving zero heavy drinking days. The announcement stresses that these endpoints are recognized by the FDA as registrational, positioning pemvidutide as a potential new therapy for AUD. Altimmune underlines the novelty of RECLAIM as the first Phase 2 multicenter study of a dual glucagon-GLP-1 agonist in AUD to report results, and points to a generally favorable tolerability profile. The company also highlights its upcoming End-of-Phase 2 meeting with the FDA in December to discuss the Phase 3 registrational program, signaling regulatory momentum. The tone is confident, focusing on regulatory designations (Fast Track for MASH and AUD, Breakthrough Therapy for MASH) and the breadth of pemvidutide’s development program, but does not provide detailed efficacy or safety data in this release.

What the data suggests

The disclosed facts confirm that the RECLAIM Phase 2 trial randomized approximately 100 adults with AUD and BMI >25 kg/m2 to receive either 2.4 mg pemvidutide or placebo once weekly for 24 weeks. The trial’s primary endpoint was a reduction in average heavy drinking days per week, with secondary endpoints including a 2-level reduction in WHO Risk Drinking Levels, zero heavy drinking days, and changes in the biomarker PEth. The company reports that pemvidutide met the primary and key secondary endpoints with statistical significance, but does not disclose the magnitude of effect, responder rates, or adverse event frequencies. The acceptance of a late-breaking oral presentation at a major liver conference suggests the findings are novel and potentially impactful, but the absence of granular data limits independent assessment of clinical relevance. The company’s regulatory strategy is clear, with a scheduled FDA End-of-Phase 2 meeting in December to discuss Phase 3 plans. The broader pipeline includes ongoing or recently completed trials in MASH and ALD, with Fast Track and Breakthrough Therapy designations supporting the program’s regulatory profile. No financial, revenue, or cost data are disclosed.

Analysis

The announcement is upbeat, highlighting the acceptance of a late-breaking oral presentation and the achievement of primary and key secondary endpoints in a Phase 2 trial. However, the actual measurable progress is limited by the absence of detailed numerical efficacy or safety data—no specific reductions, percentages, or adverse event rates are disclosed. While the company claims statistically significant results and FDA-recognized endpoints, these are not substantiated with hard numbers in this release. The forward-looking content is limited to the upcoming FDA meeting and future development plans, with most claims referencing already-completed trial milestones. There is no mention of capital outlay or immediate commercial impact, and the next steps (Phase 3 planning) indicate that any potential benefits are still years away. The tone is somewhat inflated by emphasizing regulatory designations and the novelty of the trial, but the lack of granular data tempers the overall signal.

Risk flags

• ●The absence of detailed efficacy and safety data from the RECLAIM trial prevents independent assessment of the magnitude and clinical relevance of the reported benefits, raising uncertainty about the true effect size and risk profile.
• ●Progression to Phase 3 and eventual approval for AUD will depend on FDA feedback at the upcoming End-of-Phase 2 meeting; regulatory requirements could change or require additional studies, introducing execution risk.
• ●The company’s pipeline is concentrated around pemvidutide, increasing dependency on the success of this single asset across multiple indications, which amplifies the impact of any clinical or regulatory setbacks.
• ●No financial or operational cost data are provided, making it difficult to assess the company’s ability to fund late-stage trials or withstand delays, which is a material risk for investors in clinical-stage biopharma.

Bottom line

Altimmune’s announcement signals regulatory and clinical progress for pemvidutide in alcohol use disorder, with positive Phase 2 results accepted for a high-profile late-breaking oral presentation and an FDA End-of-Phase 2 meeting imminent. The company claims achievement of both primary and key secondary endpoints recognized by the FDA, but does not provide specific numerical efficacy or safety data, limiting independent evaluation of the results’ significance. The program benefits from Fast Track and Breakthrough Therapy designations, and the RECLAIM trial’s novelty as the first Phase 2 multicenter study of a dual glucagon-GLP-1 agonist in AUD adds scientific interest. However, the lack of detailed data and the long timeline to potential commercialization mean that the investment case remains speculative and highly dependent on future disclosures and regulatory outcomes. Investors should watch for the FDA meeting outcome and the release of full trial data as the next critical catalysts. The most important takeaway is that while regulatory momentum is building, the absence of granular results and the need for successful Phase 3 execution keep risk high.

Announcement summary

(NASDAQ:ALT) Altimmune, Inc. announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD) has been accepted as an oral presentation at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2026, taking place November 5-9, 2026. The RECLAIM trial is a randomized, double-blind, placebo-controlled study evaluating once-weekly pemvidutide 2.4 mg versus placebo over 24 weeks in approximately 100 patients with BMI >25 kg/m2. In topline results announced in July 2026, pemvidutide achieved the trial’s primary endpoint of a statistically significant reduction in heavy drinking days (HDD) per week compared with placebo. Pemvidutide also met key secondary endpoints validated by the U.S. Food and Drug Administration (FDA) as registrational endpoints, including reduction in World Health Organization (WHO) Risk Drinking Levels and zero HDD, with a generally favorable tolerability profile. The late-breaking oral presentation, titled 'Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial,' will be delivered by Henry R. Kranzler, M.D., Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine, on Monday, November 9, 2026, at 10:30 a.m. MT / 12:30 p.m. ET. A copy of the presentation will be accessible on the Events section of the Altimmune website immediately following the session. Altimmune is scheduled to meet with the FDA in December for an End-of-Phase 2 meeting to discuss the Phase 3 registrational program for pemvidutide in AUD. RECLAIM (NCT06987513) is the first Phase 2 multicenter study evaluating a dual glucagon-GLP-1 agonist in AUD to report results. The primary endpoint was the change from baseline in the average number of heavy drinking days per week, with secondary endpoints including the proportion of patients achieving a 2-level reduction in WHO Risk Drinking Levels, zero HDD, and absolute change from baseline in average levels of phosphatidylethanol (PEth), an objective serum biomarker of alcohol intake. The FDA recognizes the 2-level reduction in WHO risk drinking levels and zero HDD as registrational endpoints. Pemvidutide is a novel investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), AUD, and alcohol-associated liver disease (ALD). The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, Altimmune announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial of pemvidutide in MASH was initiated. In August 2026, Altimmune announced completion of enrollment of the RESTORE Phase 2 trial in ALD.

Disagree with this article?